When combined with letrozole, the three approved CDK4/6 inhibitors—palbociclib, ribociclib, and abemaciclib—have each reported significant improvements in PFS compared with letrozole alone as first-line treatment for women with HR+, HER2− advanced breast cancer whose disease recurred more than 12 months after completing adjuvant ET. This evidence concerns the gene HR and breast carcinoma.